IPSC vs. FDMT, IPHA, VTYX, DERM, PBYI, DMAC, SPRO, ALMS, DRUG, and VYGR
Should you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include 4D Molecular Therapeutics (FDMT), Innate Pharma (IPHA), Ventyx Biosciences (VTYX), Journey Medical (DERM), Puma Biotechnology (PBYI), DiaMedica Therapeutics (DMAC), Spero Therapeutics (SPRO), Alumis (ALMS), Bright Minds Biosciences (DRUG), and Voyager Therapeutics (VYGR). These companies are all part of the "pharmaceutical products" industry.
Century Therapeutics vs. Its Competitors
4D Molecular Therapeutics (NASDAQ:FDMT) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.
4D Molecular Therapeutics has a beta of 2.81, suggesting that its stock price is 181% more volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500.
Century Therapeutics has higher revenue and earnings than 4D Molecular Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, 4D Molecular Therapeutics had 6 more articles in the media than Century Therapeutics. MarketBeat recorded 8 mentions for 4D Molecular Therapeutics and 2 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 0.49 beat 4D Molecular Therapeutics' score of 0.15 indicating that Century Therapeutics is being referred to more favorably in the news media.
Century Therapeutics has a net margin of -19.10% compared to 4D Molecular Therapeutics' net margin of -767,126.06%. Century Therapeutics' return on equity of -10.71% beat 4D Molecular Therapeutics' return on equity.
4D Molecular Therapeutics currently has a consensus price target of $29.56, indicating a potential upside of 598.71%. Century Therapeutics has a consensus price target of $4.20, indicating a potential upside of 656.76%. Given Century Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Century Therapeutics is more favorable than 4D Molecular Therapeutics.
99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 9.6% of 4D Molecular Therapeutics shares are owned by insiders. Comparatively, 5.0% of Century Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Century Therapeutics beats 4D Molecular Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Century Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Century Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:IPSC) was last updated on 7/3/2025 by MarketBeat.com Staff
Free IPSC Stock Alerts